Prospective 24-week, Double-blind, Randomised, Placebo-controlled, Multicenter Study Evaluating Safety and Change in Efficacy-related Surrogate Parameters in Patients With Dementia of the Alzheimer's Type Under Treatment With Increasing Dosages of Intravenous Immunoglobulin (Octagam 10%).

Trial Profile

Prospective 24-week, Double-blind, Randomised, Placebo-controlled, Multicenter Study Evaluating Safety and Change in Efficacy-related Surrogate Parameters in Patients With Dementia of the Alzheimer's Type Under Treatment With Increasing Dosages of Intravenous Immunoglobulin (Octagam 10%).

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2014

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Alzheimer's disease
  • Focus Biomarker; Pharmacodynamics; Registrational
  • Sponsors Octapharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Feb 2013 New source identified and integrated (European Clinical Trials Database; EudraCT2007-007134-19).
    • 20 Jul 2011 Results presented at the 2011 International Conference on Alzheimer's Disease.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top